David Vivas-Consuelo

Prof. Dr. David Vivas-Consuelo

Research Unit for Health Economics and Management, Universitat Politècnica de València, 46022 Valencia, Spain
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2013 in SpringerPlus
Verified
Journal Article
Open access
PDF file
MRMartin Romero
Martin Romero
David Vivas-ConsueloDavid Vivas-Consuelo
David Vivas-Consuelo
NANelson Alvis-Guzman
Nelson Alvis-Guzman
The purpose of this review is to do a discussion about the use of the HRQoL as a health measure of the populations that enable to analyze its potential use as a measure of development and efficiency of health systems. The principal use of the HRQoL is in health technologies economics evaluation; however this measure can be use in public health when need to know the health state of population. The WHO recognizes its potential use but its necessary to do a discussion about your difficulties for its application and restrictions for its use as a performance indicator for the health systems. The review show the different aspects about the use of HRQoL how a measure of efficiency ot the health system, each aspect identified in the literature is analyzed and discussed, developing the pros and cons of their possible use, especially when it comes as a cardinal measure. The analysis allows recognize that measuring HRQoL in countries could serve as a useful indicator, especially when it seeks to measure the level of health and disease, as do most of the indicators of current use. However, the methodological constraints that do not allow comparability between countries especially when you have large socioeconomic differences have yet to be resolved to allow comparison between different regions.

1 August 2000 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
AAA. Ament
A. Ament
RBR. Baltussen
R. Baltussen
GDG. Duru
G. Duru
CRC. Rigaud-Bully
C. Rigaud-Bully
DGD. de Graeve
D. de Graeve
DFD. S. Fedson
D. S. Fedson
Pneumococcal vaccination of older persons is thought to be cost-effective in preventing pneumococcal pneumonia, but evidence of clinical protection i

Julio Emilio Marco-FrancoJulio Emilio Marco-Franco
Julio Emilio Marco-Franco
PPPedro Pita-Barros
Pedro Pita-Barros
David Vivas-OrtsDavid Vivas-Orts
David Vivas-Orts
SGSilvia González-de-Julián
Silvia González-de-Julián
David Vivas-ConsueloDavid Vivas-Consuelo
David Vivas-Consuelo
We analysed issues concerning the establishment of compulsory vaccination against COVID-19, as well as the role of misinformation as a disincentive—especially when published by health professionals—and citizen acceptance of measures in this regard. Data from different surveys revealed a high degree of hesitation rather than outright opposition to vaccines. The most frequent complaint related to the COVID-19 vaccination was the fear of side effects. Within the Spanish and European legislative framework, both compulsory vaccination and government regulation of FN (Fake News) appear to be feasible options, counting on sufficient legal support, which could be reinforced by additional amendment. However, following current trends of good governance, policymakers must have public legitimation. Rather than compulsory COVID-19 vaccination, an approach based on education and truthful information, persuading the population of the benefits of a vaccine on a voluntary basis, is recommended. Disagreements between health professionals are positive, but they should be resolved following good practice and the procedures of the code of ethics. Furthermore, citizens do not support the involvement of government authorities in the direct control of news. Collaboration with the media and other organizations should be used instead.

1 October 2010 in Mathematical and Computer Modelling
Verified
Journal Article
Closed access
MCMaría Caballer-Tarazona
María Caballer-Tarazona
ICIsmael Moya Clemente
Ismael Moya Clemente
David Vivas-ConsueloDavid Vivas-Consuelo
David Vivas-Consuelo
IBIsabel Barrachina-Martínez
Isabel Barrachina-Martínez

14 May 2016 in Health Economics Review
Verified
Journal Article
Open access
PDF file
MCMaría Caballer-Tarazona
María Caballer-Tarazona
David Vivas-ConsueloDavid Vivas-Consuelo
David Vivas-Consuelo
Public-private partnership (PPP) initiatives are extending around the world, especially in Europe, as an innovation to traditional public health systems, with the intention of making them more efficient. There is a varied range of PPP models with different degrees of responsibility from simple public sector contracts with the private, up to the complete privatisation of the service. As such, we may say the involvement of the private sector embraces the development, financing and provision of public infrastructures and delivery services. In this paper, one of the oldest PPP initiatives developed in Spain and transferred to other European and Latin American countries is evaluated for first time: the integrated healthcare delivery Alzira model. Through a comparison of public and PPP hospital performance, cost and quality indicators, the efficiency of the PPP experience in five hospitals is evaluated to identify the influence of private management in the results. Regarding the performance and efficiency analysis, it is seen that the PPP group obtains good results, above the average, but not always better than those directly managed. It is necessary to conduct studies with a greater number of PPP hospitals to obtain conclusive results.

17 August 2016 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
CSCarla Sancho-Mestre
Carla Sancho-Mestre
David Vivas-ConsueloDavid Vivas-Consuelo
David Vivas-Consuelo
LALuis Alvis-Estrada
Luis Alvis-Estrada
MRMartin Romero
Martin Romero
RURuth Usó-Talamantes
Ruth Usó-Talamantes
VCVicent Caballer-Tarazona
Vicent Caballer-Tarazona
The objective of the study is to estimate the frequency of multimorbidity in type 2 diabetes patients classified by health statuses in a European region and to determine the impact on pharmaceutical expenditure. Cross-sectional study of the inhabitants of a southeastern European region with a population of 5,150,054, using data extracted from Electronic Health Records for 2012. 491,854 diabetic individuals were identified and selected through clinical codes, Clinical Risk Groups and diabetes treatment and/or blood glucose reagent strips. Patients with type 1 diabetes and gestational diabetes were excluded. All measurements were obtained at individual level. The prevalence of common chronic diseases and co-occurrence of diseases was established using factorial analysis. The estimated prevalence of diabetes was 9.6 %, with nearly 70 % of diabetic patients suffering from more than two comorbidities. The most frequent of these was hypertension, which for the groups of patients in Clinical Risk Groups (CRG) 6 and 7 was 84.3 % and 97.1 % respectively. Regarding age, elderly patients have more probability of suffering complications than younger people. Moreover, women suffer complications more frequently than men, except for retinopathy, which is more common in males. The highest use of insulins, oral antidiabetics (OAD) and combinations was found in diabetic patients who also suffered cardiovascular disease and neoplasms. The average cost for insulin was 153€ and that of OADs 306€. Regarding total pharmaceutical cost, the greatest consumers were patients with comorbidities of respiratory illness and neoplasms, with respective average costs of 2,034.2€ and 1,886.9€. Diabetes is characterized by the co-occurrence of other diseases, which has implications for disease management and leads to a considerable increase in consumption of medicines for this pathology and, as such, pharmaceutical expenditure.